Free Trial

HUTCHMED (LON:HCM) Stock Price Passes Below 200-Day Moving Average - Time to Sell?

HUTCHMED logo with Medical background
Remove Ads

HUTCHMED (China) Limited (LON:HCM - Get Free Report)'s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 261.04 ($3.37) and traded as low as GBX 248 ($3.21). HUTCHMED shares last traded at GBX 248 ($3.21), with a volume of 20,179 shares traded.

HUTCHMED Price Performance

The stock has a market cap of £2.58 billion, a PE ratio of -60.74 and a beta of 0.76. The business's 50-day simple moving average is GBX 235.37 and its 200-day simple moving average is GBX 260.86. The company has a quick ratio of 2.97, a current ratio of 2.81 and a debt-to-equity ratio of 11.97.

About HUTCHMED

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).

Featured Stories

Should You Invest $1,000 in HUTCHMED Right Now?

Before you consider HUTCHMED, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.

While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!
Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads